secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001682852-23-000008
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q4 net income down 70% to $1.5B; FY2022 revenue $19.3B; reiterates $5B COVID sales for 2023
--------------------------------------------------------------------------------

- Q4 2022 revenue $5.1B (down 29% YoY from $7.2B); GAAP diluted EPS $3.61 (down 68% from $11.29).
- Full-year 2022 revenue $19.3B (up 4% from $18.5B); GAAP net income $8.4B (down 31% from $12.2B); diluted EPS $20.12.
- Cost of sales surged to 39% of product sales in Q4 (from 14% YoY) due to $297M inventory write-downs, $281M purchase commitment losses, $376M unutilized capacity charges.
- R&D spending increased 87% to $1.2B in Q4; full-year R&D $3.3B (up 65%); 2023 R&D guidance $4.5B.
- Juan Andres, President of Strategic Partnerships, to retire in May 2023; Jerh Collins joined as CTOO in October 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000008/0001682852-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000008/mrna-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001682852-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer